Latest Posts › Life Sciences

Share:

Key Considerations for Healthcare Providers Responding to Law Enforcement Requests

Why is everyone talking about provider disclosures to law enforcement of late? The Senate Finance Committee authored a letter to Xavier Becerra, Secretary of the U.S. Department of Health and Human Services (HHS), outlining...more

Diving into the Washington My Health My Data Act : Part Nine: Enforcement and Private Right of Action

This is Part Nine in a series of legal updates on the Washington My Health My Data (“WMHMDA”) where Quarles continues its deep dive into the various factors and intricacies of WMHMDA that are creating waves in the privacy...more

Diving into the Washington My Health My Data Act - Part Seven: Biometric Data

This is Part Seven in a series of legal updates on the Washington My Health My Data (“WMHMDA”), where Quarles continues its deep dive into the various factors and intricacies of WMHMDA that are creating waves in the privacy...more

Final Definitions and Considerations for Trading Partners to Prepare for DSCSA Implementation

On March 16, 2023, the Food and Drug Administration (FDA) released final guidance regarding definitions of "suspect product" and "illegitimate product" as part of a continued effort to prepare trading partners for the...more

CPRA is in Effect: What Health and Life Sciences Entities Need to Know

The long-awaited January 1, 2023 effective date of the California Privacy Rights Act (CPRA) has arrived and cannot be ignored or dismissed any longer. Many health care entities are aware of the Health Insurance Portability...more

5 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide